Tweetorial: Subtle Symptoms of Tardive Dyskinesia Have a Huge Impact on Early Recognition and Intervention
Tweetorial: Subtle Symptoms of Tardive Dyskinesia Have a Huge Impact on Early Recognition and Intervention is organized by CME Institute of Physicians Postgraduate Press, Inc. (PPP).
Activity opens: 01/18/2023
Activity expires: 01/31/2024
Overview:
In this Tweetorial learn the causes, signs and symptoms, assessments tools, and treatments for the medication-induced movement disorder tardive dyskinesia.
Statement of Need and Purpose:
Clinicians who treat patients with dopamine receptor blocking agents—such as antipsychotics for schizophrenia, bipolar disorder, or major depression—need to consider the risk for tardive dyskinesia (TD), educate patients and their families about the risk and early signs, recognize early symptoms, and provide treatment. A substantial proportion of patients with TD do not have a timely diagnosis, meaning that treatment is delayed and the chance for a poor outcome is increased. Because some clinicians underestimate the risk of TD, especially with newer antipsychotics, they do not advise patients about the risk of TD, educate them about early signs to watch for and report, or conduct routine screenings. Effective medications for TD should be implemented as appropriate, incorporating data on the functional impact of TD on the patient. Clinicians need education on evidence?based, expert?consensus care for TD.
Program Description:
Tardive dyskinesia (TD) is a medication-induced movement disorder that can last decades and is often a permanent condition. TD affects 25% to 30% of patients taking antipsychotic medications and 26% to 67% of patients on long-term dopamine antagonists. Clinicians should regularly screen patients with a history of neuroleptic use for signs and symptoms of TD, such as dystonia, buccolingual stereotypy, chorea, akathisia, tics, or other abnormal involuntary movements, particularly if they appear within 1 to 2 years of continuous exposure to the medication. However, TD can appear earlier, especially in the elderly population. A differential diagnosis requires excluding other involuntary movements such as habits, mannerisms, paroxysmal dyskinesias, and benign hereditary chorea and other disorders, including myoclonus, dystonia, tics, and chorea. Structured instruments for TD assessment include the Abnormal Involuntary Movement Scale (AIMS) and the Dyskinesia Identification System: Condensed User Scale (DISCUS). These screenings should be administered at the time of new onset or exacerbation of an existing movement disorder as well as every 6 months to patients at high risk of developing TD and every 12 months to other patients. Educating patients and families about the risk of TD associated with chronic neuroleptic use as well as signs and symptoms of the disorder are an important piece in earlier invention of this distressing disorder, improving quality of life and leading to better patient outcomes.
Learning Objective:
After completing this educational activity, you should be able to:
• Use best practices that are based on evidence and expert consensus to screen for and manage TD.